中华口腔医学研究杂志(电子版)
中華口腔醫學研究雜誌(電子版)
중화구강의학연구잡지(전자판)
CHINESE JOURNAL OF STOMATOLOGICAL RESEARCH(ELECTRONIC VERSION)
2014年
5期
386-391
,共6页
梁培盛%蒋盼%肖栋涛%杨菁%凌均棨%汪华
樑培盛%蔣盼%肖棟濤%楊菁%凌均棨%汪華
량배성%장반%초동도%양정%릉균계%왕화
口腔%癌,鳞状细胞%改良的细胞因子诱导杀伤细胞%生存分析
口腔%癌,鱗狀細胞%改良的細胞因子誘導殺傷細胞%生存分析
구강%암,린상세포%개량적세포인자유도살상세포%생존분석
Oral%Squamous cell carcinoma%Improved cytokine-induced killer cells%Survival analysis
目的研究改良的细胞因子诱导杀伤细胞(iCIK)过继性治疗口腔鳞状细胞癌(OSCC)的疗效。方法回顾2008年7月至2013年4月60例OSCC患者,根据治疗方式分为iCIK组(手术治疗+iCIK治疗)及对照组(手术治疗),不良预后者术后行放疗或放化疗。统计两组的复发转移率、生存率、无病生存期及总生存期。分析iCIK组培养前后外周血单个核细胞(PBMC)及iCIK细胞的T细胞亚群比例及Th1细胞因子分泌水平。结果 iCIK组复发转移率低于对照组(16.67%vs 40.00%,χ2=4.022, P=0.045),且无病生存期高于对照组(50.96±3.69 vs 38.15±4.90,χ2=4.163,P=0.041)。但两组的死亡率及总体生存期差异无统计学意义。 iCIK培养后T细胞及CTL细胞比例、IL-2及IFN-γ水平显著增高。不良反应发生率为1.17%,无严重不良反应。结论 iCIK辅助治疗可延长OSCC患者无病生存期,减少复发或转移的发生,但未改变最终的预后,长期疗效有待进一步观察。 iCIK高表达CD3+CD8+,分泌高浓度的Th1细胞因子,具有较强的细胞免疫及抗肿瘤能力,且治疗安全性良好。
目的研究改良的細胞因子誘導殺傷細胞(iCIK)過繼性治療口腔鱗狀細胞癌(OSCC)的療效。方法迴顧2008年7月至2013年4月60例OSCC患者,根據治療方式分為iCIK組(手術治療+iCIK治療)及對照組(手術治療),不良預後者術後行放療或放化療。統計兩組的複髮轉移率、生存率、無病生存期及總生存期。分析iCIK組培養前後外週血單箇覈細胞(PBMC)及iCIK細胞的T細胞亞群比例及Th1細胞因子分泌水平。結果 iCIK組複髮轉移率低于對照組(16.67%vs 40.00%,χ2=4.022, P=0.045),且無病生存期高于對照組(50.96±3.69 vs 38.15±4.90,χ2=4.163,P=0.041)。但兩組的死亡率及總體生存期差異無統計學意義。 iCIK培養後T細胞及CTL細胞比例、IL-2及IFN-γ水平顯著增高。不良反應髮生率為1.17%,無嚴重不良反應。結論 iCIK輔助治療可延長OSCC患者無病生存期,減少複髮或轉移的髮生,但未改變最終的預後,長期療效有待進一步觀察。 iCIK高錶達CD3+CD8+,分泌高濃度的Th1細胞因子,具有較彊的細胞免疫及抗腫瘤能力,且治療安全性良好。
목적연구개량적세포인자유도살상세포(iCIK)과계성치료구강린상세포암(OSCC)적료효。방법회고2008년7월지2013년4월60례OSCC환자,근거치료방식분위iCIK조(수술치료+iCIK치료)급대조조(수술치료),불량예후자술후행방료혹방화료。통계량조적복발전이솔、생존솔、무병생존기급총생존기。분석iCIK조배양전후외주혈단개핵세포(PBMC)급iCIK세포적T세포아군비례급Th1세포인자분비수평。결과 iCIK조복발전이솔저우대조조(16.67%vs 40.00%,χ2=4.022, P=0.045),차무병생존기고우대조조(50.96±3.69 vs 38.15±4.90,χ2=4.163,P=0.041)。단량조적사망솔급총체생존기차이무통계학의의。 iCIK배양후T세포급CTL세포비례、IL-2급IFN-γ수평현저증고。불량반응발생솔위1.17%,무엄중불량반응。결론 iCIK보조치료가연장OSCC환자무병생존기,감소복발혹전이적발생,단미개변최종적예후,장기료효유대진일보관찰。 iCIK고표체CD3+CD8+,분비고농도적Th1세포인자,구유교강적세포면역급항종류능력,차치료안전성량호。
Objective To investigate effect of improved cytokine-induced killer cells (iCIK) adoptive cellular therapy on patients with oral squamous cell carcinoma (OSCC). Methods Sixty OSCC patients between 2008 July to 2013 April have been surveyed retrospectively and are classified into iCIK group (surgery and iCIK therapy) or Control group (surgery). Those with adverse features received radiotherapy or chemo-radiotherapy additionally. The recurrence or metastasis rate, survival rate, disease-free survival time (DFS) and overall survival time (OS) of two groups are compared. In iCIK group, percentage of T cells subpopulations and concentrations of Th1 cell cytokines are detected between peripheral blood mononuclear cells (PBMC) and iCIK. Results The recurrence or metastasis rate in iCIK group is lower than that of the Control (16.67% vs 40.00%,χ2=4.022, P=0.045). Meanwhile, the DFS means of the former is longer than that of the latter (50.96 ± 3.69 vs 38.15 ± 4.90, χ2=4.163, P=0.041). Unfortunately, it has no significant difference between two groups in death rate and OS . After iCIK cultured, the percentages of T cell and CTL subpopulations, concentrations of IL-2 and IFN-γ of iCIK have been enhanced. Adverse reaction rate is 1.17%, without severe toxic effect. Conculsions iCIK prolong DFS and reduce the risk of recurrence and metastasis in OSCC . But it cannot improve prognosis significantly and acquire continuous observation to evaluate for long-term therapeutic efficacy . iCIK, a major subset of CD3+CD8+, are able to secrete high concentration of Th1 cell cytokines to eradicate or reduce tumor in cellular immunity. iCIK is a potential reliable therapy in safety.